Health Care

NewcelX Ltd. files Pre‑IND for NCEL‑101, a novel type 1 diabetes therapy, marking a major step toward clinical trials and expanding its biopharma portfolio.

Elite Pharmaceuticals: market volatility, controlled‑release drug innovation, and potential growth prospects amid regulatory and competitive challenges.

Ocugen’s new Russell 3000 spot boosts liquidity, attracts ETFs, and could lift its stock as a clinical‑stage biotech gains visibility in the U.S. market.

Newron Pharmaceuticals’ CNS‑focused research faces stark financial challenges—negative P/E, volatile share price, and low market cap threaten investor confidence and future growth.

Discover how Kuros Biosciences AG’s orthobiologics are redefining bone repair—high‑growth biotech, Swiss‑listed, and reshaping orthopedic medicine worldwide.

Jiangsu Hengrui Pharmaceuticals is positioning itself to capture the growing soft‑tissue sarcoma market, leveraging new targeted therapies, regulatory progress, and a solid financial base to become a leading oncology innovator.

Clinuvel Pharmaceuticals’ surge in ASX shares reflects its strategic focus on innovative UV‑related dermatology solutions, positioning it as a biotech leader with solid growth prospects.

Vaxart’s oral flu vaccines harness gut immunity for safer, global vaccination, reshaping biotech with a digital-first, mucosal‑focused approach.

Apimeds Pharmaceuticals US Inc: Bitcoin treasury solutions, volatile stock, unique UAE‑based digital asset strategy, potential growth amid market challenges.

Hedera Group AB faces legal scrutiny over its 2022 Libra Assistans acquisition, risking 6.2 M SEK and potential share‑price decline. This article explains the court’s impact, risk management, and future steps for the Stockholm recruitment firm.